Tags

Type your tag names separated by a space and hit enter

DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Science. 2020 08 14; 369(6505):806-811.Sci

Abstract

The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers at levels comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. After vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with viral loads in sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.

Authors+Show Affiliations

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.Bioqual, Rockville, MD 20852, USA.Bioqual, Rockville, MD 20852, USA.Bioqual, Rockville, MD 20852, USA.Bioqual, Rockville, MD 20852, USA.Bioqual, Rockville, MD 20852, USA.Bioqual, Rockville, MD 20852, USA.Bioqual, Rockville, MD 20852, USA.Bioqual, Rockville, MD 20852, USA.Bioqual, Rockville, MD 20852, USA.Janssen Vaccines & Prevention BV, Leiden, Netherlands.Janssen Vaccines & Prevention BV, Leiden, Netherlands.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.Children's Hospital, Boston, MA 02115, USA.Children's Hospital, Boston, MA 02115, USA. Massachusetts Consortium on Pathogen Readiness, Boston, MA 02215, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Massachusetts Consortium on Pathogen Readiness, Boston, MA 02215, USA.Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Massachusetts Consortium on Pathogen Readiness, Boston, MA 02215, USA.Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Massachusetts Consortium on Pathogen Readiness, Boston, MA 02215, USA.Bioqual, Rockville, MD 20852, USA.Bioqual, Rockville, MD 20852, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. dbarouch@bidmc.harvard.edu. Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Massachusetts Consortium on Pathogen Readiness, Boston, MA 02215, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32434945

Citation

Yu, Jingyou, et al. "DNA Vaccine Protection Against SARS-CoV-2 in Rhesus Macaques." Science (New York, N.Y.), vol. 369, no. 6505, 2020, pp. 806-811.
Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369(6505):806-811.
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., Martinez, D. R., Loos, C., Atyeo, C., Fischinger, S., Burke, J. S., Slein, M. D., Chen, Y., Zuiani, A., Lelis, F. J. N., ... Barouch, D. H. (2020). DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science (New York, N.Y.), 369(6505), 806-811. https://doi.org/10.1126/science.abc6284
Yu J, et al. DNA Vaccine Protection Against SARS-CoV-2 in Rhesus Macaques. Science. 2020 08 14;369(6505):806-811. PubMed PMID: 32434945.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - DNA vaccine protection against SARS-CoV-2 in rhesus macaques. AU - Yu,Jingyou, AU - Tostanoski,Lisa H, AU - Peter,Lauren, AU - Mercado,Noe B, AU - McMahan,Katherine, AU - Mahrokhian,Shant H, AU - Nkolola,Joseph P, AU - Liu,Jinyan, AU - Li,Zhenfeng, AU - Chandrashekar,Abishek, AU - Martinez,David R, AU - Loos,Carolin, AU - Atyeo,Caroline, AU - Fischinger,Stephanie, AU - Burke,John S, AU - Slein,Matthew D, AU - Chen,Yuezhou, AU - Zuiani,Adam, AU - Lelis,Felipe J N, AU - Travers,Meghan, AU - Habibi,Shaghayegh, AU - Pessaint,Laurent, AU - Van Ry,Alex, AU - Blade,Kelvin, AU - Brown,Renita, AU - Cook,Anthony, AU - Finneyfrock,Brad, AU - Dodson,Alan, AU - Teow,Elyse, AU - Velasco,Jason, AU - Zahn,Roland, AU - Wegmann,Frank, AU - Bondzie,Esther A, AU - Dagotto,Gabriel, AU - Gebre,Makda S, AU - He,Xuan, AU - Jacob-Dolan,Catherine, AU - Kirilova,Marinela, AU - Kordana,Nicole, AU - Lin,Zijin, AU - Maxfield,Lori F, AU - Nampanya,Felix, AU - Nityanandam,Ramya, AU - Ventura,John D, AU - Wan,Huahua, AU - Cai,Yongfei, AU - Chen,Bing, AU - Schmidt,Aaron G, AU - Wesemann,Duane R, AU - Baric,Ralph S, AU - Alter,Galit, AU - Andersen,Hanne, AU - Lewis,Mark G, AU - Barouch,Dan H, Y1 - 2020/05/20/ PY - 2020/05/05/received PY - 2020/05/16/accepted PY - 2020/5/22/pubmed PY - 2020/8/28/medline PY - 2020/5/22/entrez SP - 806 EP - 811 JF - Science (New York, N.Y.) JO - Science VL - 369 IS - 6505 N2 - The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers at levels comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. After vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with viral loads in sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates. SN - 1095-9203 UR - https://www.unboundmedicine.com/medline/citation/32434945/DNA_vaccine_protection_against_SARS_CoV_2_in_rhesus_macaques_ L2 - https://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=32434945 DB - PRIME DP - Unbound Medicine ER -